Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

[Hazelgreen]

This "updated exploratory analysis" (aacrjournals.org/clincancer... indicates: "superior overall survival (OS) outcomes with palbociclib plus fulvestrant compared with fulvestrant alone in patients with HR+/HER2− advanced breast cancer who had progressed on prior endocrine therapy. The favorable OS associated with palbociclib was observed across most subgroups, regardless of ESR1, PIK3CA, or TP53 mutation status."

[Hopefulwmbc]

Wonderful! Just when I am progressing. Good bye, Ibrance.

[TammyCross in reply to Hopefulwmbc]

Exactly! For those of us for whom Palbo has already failed, I guess this doesn't mean much. Got about 2 years out of it. How do they factor that in? There is a stat or measure we used to use in policing research: time to failure.

[Melpub]

This is very nice, in the sense that I'd progressed and was then on Ibrance and Faslodex for about 4.5 years, but now the new stuff (generic of Avastin) gave me a blood pressure of 150/94 and higher. Me, who was always dizzy from low blood pressure. Yeeks.

[8576]

Don' forget to ask for a lower dose. Sometimes that works.

Cheers, June S.

[Tolife_18]

Thank you so much for sharing this article. Although not data was provided, the analysis is quite comprehensive. Not only the patients were followed up for 6 years, impact on mutations on OS and PFS was investigated.

I encourage you to t

Read the entire article, not just an abstract.

Which lead me to a question. How many of you had liquid biopsy? I didn’t, although biopsy results included mutations.

It would be great periodically have a liguid biopsy to determine that ER and HERG status remains the same and there are no change in the mutations.

All the best to you!

[TammyCross in reply to Tolife_18]

So I read most of it, as you recommended. Eighty percent of those in the treatment group (palbo + fulvestrant) were dead after six years? I started Ibrance +fulvestrant in 2019, so I have 3 years? That may be about right. I went on to other treatments in 2021. Doesn't factor in the success of these subsequent meds, though. It was a Stage 3 trial. The people in the control group (fulvestrant + placebo) died faster. Wouldn't have liked to be randomly assigned to control.

I guess I am putting a negative spin on "good news."

[TammyCross in reply to TammyCross]

Oh, and I have had one liquid biopsy. I had to ask for it. It showed no mutations, good to know. I guess I will wait until next progression before asking for another.

[Tolife_18 in reply to TammyCross]

As you know, it’s all individual and the science still figuring out what factors are leading to better outcome. This is why I found interesting the analysis in the subgroups like various mutations. Also, it seems that patients who didn’t received prior chemo doing better

Again, the results are preliminary and I’d not focus specifically on the survival data.

We need to hang out long enouph for another line of therapy to come along 😊.

[Flag1947]

I am 75 and have been on fluvescent/Ibrance for 3 years.

It appears to be working.

[Aprilfoolz1]

thanks for posting !